OneMedNet Regains Compliance with NASDAQ Listing Requirements
OneMedNet (ONMD) has regained compliance with Nasdaq Listing Rule 5550(b)(2) after its common stock market value exceeded $35,000,000 for 10 consecutive business days. The company has cleared all listing deficiency notices issued by Nasdaq.
Throughout 2024-2025, OneMedNet implemented several strategic initiatives, including: expanding product offerings with data masking solutions and subscription-based services; appointing key executives including Bob Golden as CFO; signing an agreement with Bayer's AI Innovation Platform; enhancing data de-identification services with Generative AI; deploying the OMNi 2.0 indexer; refreshing the Board of Directors; and improving liquidity through $6.4M in private placements with Off the Chain Capital and Discovery Capital Management affiliate. The company also implemented a Bitcoin treasury management strategy.
OneMedNet (ONMD) ha riacquistato la conformità con la Regola di quotazione di Nasdaq 5550(b)(2) dopo che il valore di mercato delle sue azioni ordinarie ha superato i 35.000.000 di dollari per 10 giorni lavorativi consecutivi. L'azienda ha superato tutte le notifiche di carenza di quotazione emesse da Nasdaq.
Nel corso del 2024-2025, OneMedNet ha implementato diverse iniziative strategiche, tra cui: l'espansione dell'offerta di prodotti con soluzioni di mascheramento dei dati e servizi in abbonamento; la nomina di dirigenti chiave, tra cui Bob Golden come CFO; la firma di un accordo con la piattaforma di innovazione AI di Bayer; il potenziamento dei servizi di de-identificazione dei dati con l'AI Generativa; il lancio dell'indicizzatore OMNi 2.0; il rinnovamento del Consiglio di Amministrazione; e il miglioramento della liquidità attraverso 6,4 milioni di dollari di collocamenti privati con Off the Chain Capital e Discovery Capital Management affiliate. L'azienda ha anche implementato una strategia di gestione della tesoreria in Bitcoin.
OneMedNet (ONMD) ha recuperado el cumplimiento de la Regla de Cotización 5550(b)(2) de Nasdaq después de que el valor de mercado de sus acciones ordinarias superara los 35,000,000 de dólares durante 10 días hábiles consecutivos. La compañía ha atendido todos los avisos de deficiencia de cotización emitidos por Nasdaq.
A lo largo de 2024-2025, OneMedNet implementó varias iniciativas estratégicas, incluyendo: la expansión de la oferta de productos con soluciones de enmascaramiento de datos y servicios de suscripción; la designación de ejecutivos clave, incluyendo a Bob Golden como CFO; la firma de un acuerdo con la Plataforma de Innovación AI de Bayer; la mejora de los servicios de desidentificación de datos con AI Generativa; el despliegue del indexador OMNi 2.0; la renovación de la Junta Directiva; y la mejora de la liquidez a través de 6.4 millones de dólares en colocaciones privadas con Off the Chain Capital y el afiliado Discovery Capital Management. La compañía también implementó una estrategia de gestión de tesorería en Bitcoin.
OneMedNet (ONMD)는 보통주 시장 가치가 35,000,000달러를 초과하여 10 영업일 연속으로 나스닥 상장 규정 5550(b)(2)를 준수하게 되었습니다. 이 회사는 나스닥에서 발행한 모든 상장 부족 통지를 해결했습니다.
2024-2025년 동안 OneMedNet은 데이터 마스킹 솔루션 및 구독 기반 서비스와 같은 제품 제공 확장, Bob Golden CFO 임명, Bayer의 AI 혁신 플랫폼과의 계약 체결, 생성적 AI를 통한 데이터 비식별화 서비스 개선, OMNi 2.0 인덱서 배포, 이사회 개편, Off the Chain Capital 및 Discovery Capital Management 계열사와의 640만 달러 규모의 사모 배치를 통한 유동성 개선 등 여러 전략적 이니셔티브를 구현했습니다. 또한 이 회사는 비트코인 재무 관리 전략을 도입했습니다.
OneMedNet (ONMD) a retrouvé la conformité avec la règle de cotation 5550(b)(2) de Nasdaq après que la valeur de marché de ses actions ordinaires a dépassé 35 000 000 $ pendant 10 jours de bourse consécutifs. La société a résolu tous les avis de carence de cotation émis par Nasdaq.
Au cours de 2024-2025, OneMedNet a mis en œuvre plusieurs initiatives stratégiques, notamment : l'élargissement de l'offre de produits avec des solutions de masquage de données et des services par abonnement ; la nomination de dirigeants clés, dont Bob Golden en tant que CFO ; la signature d'un accord avec la plateforme d'innovation AI de Bayer ; l'amélioration des services de déidentification des données grâce à l'IA générative ; le déploiement de l'indexeur OMNi 2.0 ; le renouvellement du conseil d'administration ; et l'amélioration de la liquidité grâce à 6,4 millions de dollars de placements privés auprès de Off the Chain Capital et de l'affilié Discovery Capital Management. L'entreprise a également mis en place une stratégie de gestion de trésorerie en Bitcoin.
OneMedNet (ONMD) hat die Einhaltung der Nasdaq-Listing-Regel 5550(b)(2) wiederhergestellt, nachdem der Marktwert seiner Stammaktien 35.000.000 Dollar an zehn aufeinander folgenden Geschäftstagen überschritten hat. Das Unternehmen hat alle von Nasdaq ausgestellten Mitteilungen über Listungsmängel beseitigt.
Im Laufe von 2024-2025 implementierte OneMedNet mehrere strategische Initiativen, darunter: die Erweiterung des Produktangebots mit Datenmaskierungslösungen und abonnementbasierten Dienstleistungen; die Ernennung von Schlüsselpersonen, darunter Bob Golden als CFO; die Unterzeichnung eines Vertrags mit der KI-Innovationsplattform von Bayer; die Verbesserung der Datenanonymisierungsdienste mit generativer KI; die Bereitstellung des OMNi 2.0-Indexers; die Auffrischung des Vorstands; und die Verbesserung der Liquidität durch 6,4 Millionen US-Dollar in Privatplatzierungen mit Off the Chain Capital und Discovery Capital Management Affiliate. Das Unternehmen implementierte auch eine Strategie für das Management der Bitcoin-Reserve.
- Regained Nasdaq compliance, eliminating delisting risk
- Secured $6.4M through private placements
- Expanded product offerings with new data masking solutions
- Signed agreement with Bayer's AI Innovation Platform
- Enhanced data services with Generative AI implementation
- None.
Insights
The regaining of NASDAQ compliance represents a critical milestone for OneMedNet, particularly given its micro-cap status with a market cap of
The
The strategic focus on iRWD™ (Imaging Real World Data) and the partnership with Bayer's AI Innovation Platform positions OneMedNet in the rapidly growing healthcare data analytics market. The implementation of AI-powered data de-identification services and the OMNi 2.0 indexer suggests a technology-forward approach to scaling operations.
The deployment of OneMedNet's 2.0 generation indexer OMNi represents a significant technological advancement in the medical imaging data space. The integration of Generative AI for data de-identification is particularly noteworthy as it addresses two critical market demands: faster processing speeds and enhanced data security compliance.
The partnership with Bayer's AI Innovation Platform (AIIP) validates OneMedNet's technological capabilities and could accelerate the company's market penetration in the pharmaceutical research sector. The expansion into data masking solutions for additional industries suggests a scalable technology stack that could open new revenue streams beyond healthcare.
However, the adoption of a Bitcoin treasury strategy raises concerns about risk management, as cryptocurrency volatility could impact the company's ability to fund its technological development roadmap.
MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data (“iRWD™”), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that the Company regained compliance with Nasdaq Listing Rule 5550(b)(2) (the “Rule”) after the market value of the Company’s common stock exceeded
Aaron Green, Chief Executive Officer, stated, “We are pleased to have now achieved compliance with the Nasdaq listing rules. This accomplishment will enable us to focus in 2025 on growing our revenue and business operations.”
During the 2024 and 2025, we developed and started to execute on our strategic plan by:
- Expanding its product offerings, which now include data masking solutions for additional industries and subscription-based offerings for the Company’s healthcare and real-world data solutions.
- Appointing Bob Golden as Chief Financial Officer to oversee enhancements in the Company’s financial reporting processes.
- Hiring a Director of Business Development, Margaret Nash, and Vice President of Marketing, Michael Wong, to continue to build our commercial presence with Life Science organizations, additionally recently signing an agreement with Bayer’s AI Innovation Platform (AIIP) announced in early December 2024.
- Enhancing our Data De-Identification and curation service leveraging Generative AI and deploying OneMedNet’s 2.0 generation indexer OMNi, to improve the speed and accuracy of data searching and indexing.
- Refreshing the composition of the Company’s Board of Directors with three new directors who have relevant industry, financial and public company expertise.
- Improving liquidity by raising approximately
$6.4M in private placements with Off the Chain Capital and an affiliate of Discovery Capital Management. - Enhancing treasury management with a Bitcoin on the balance sheet strategy.
OneMedNet is now in a position to take advantage of the growing Real World Data market with a meaningful market share.
About OneMedNet Corporation
OneMedNet provides innovative solutions that unlock the significant value contained within the Real-World Data (“RWD”) repositories of over 1,400 healthcare system and provider sites that currently comprise its iRWD™ network. OneMedNet’s proprietary iRWD™ platform provides secure, comprehensive management of diverse clinical data types, including electronic health records, ECGs, EEGs, prescriptions, physician notes, laboratory results, and uniquely, medical imaging. Employing its robust iRWD™ platform, the Company securely de-identifies, searches, and curates the clinical data, bringing a wealth of internal and third-party research opportunities to its drug, medical device and imaging/diagnostic AI development customers.
OneMedNet’s platform is designed to address diverse clinical requirements across various domains, such as rare diseases, central nervous system disorders, oncology, cardiology and women’s health. The Company is committed to delivering precise and robust research support services that span the entire continuum of care. This commitment is a cornerstone of OneMedNet’s strategy to enhance patient outcomes and help pave the next wave of healthcare innovation. For more information, please visit www.onemednet.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin’s volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: michael.wong@onemednet.com
SOURCE: ONEMEDNET CORPORATION
FAQ
How did OneMedNet (ONMD) regain Nasdaq compliance in 2025?
How much funding did ONMD raise in private placements?
What strategic partnerships did ONMD secure in 2024?
What technological improvements did ONMD implement in 2024-2025?
What new financial strategy did ONMD implement for treasury management?
